Corrigendum to: Novel synaptobrevin-1 mutation causes fatal congenital myasthenic syndrome (Annals of Clinical and Translational Neurology, (2017), 4, 2, (130-138), 10.1002/acn3.387);Novel synaptobrevin-1 mutation causes fatal congenital myasthenic syndrome

Annals of Clinical and Translational Neurology

Volumn 4, Issue 2, 2017, Pages 130-138

  Shen, Xin Ming ^a   Scola, Rosana H ^b   Lorenzoni, Paulo J ^b   Kay, Cláudia S K ^b   Werneck, Lineu C ^b   Brengman, Joan ^a   Selcen, Duygu ^a   Engel, Andrew G ^a  

^a MAYO CLINIC   (United States)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PYRIDOSTIGMINE; RAB PROTEIN; SYNAPSIN I; SYNAPTOBREVIN 1; SYNAPTOTAGMIN I; SYNAPTOTAGMIN II;

AMPEROMETRY; ARTICLE; CHROMAFFIN CELL; CONGENITAL MYASTHENIC SYNDROME; CONTROLLED STUDY; DEPOLARIZATION; ELECTROPHYSIOLOGY; EXOCYTOSIS; EXOME; FEMALE; FRAMESHIFT MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INFANT; MUSCLE ACTION POTENTIAL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SANGER SEQUENCING; SYNAPTIC TRANSMISSION; WEAKNESS;

EID: 85020480964     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.422     Document Type: Erratum

References (34)

1. Engel AG, Shen XM, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 2015;14:420–434.
2. Ohno K, Tsujino A, Shen XM, et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci USA 2001;98:2017–2022.
3. Huze C, Bauche S, Richard P, et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 2009;85:155–167.
4. Herrmann DN, Horvath R, Snowden JE, et al. Synaptotagmin 2 mutations cause an autosomal-dominant form of Lambert-Eaton myasthenic syndrome and nonprogressive motor neuropathy. Am J Hum Genet 2014;95:332–339.
5. Shen XM, Selcen D, Brengman J, et al. Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability. Neurology 2014;83:2247–2255.
6. Engel AG, Selcen D, Shen XM, et al. Loss of MUNC13-1 function causes microcephaly, cortical hyperexcitability, and fatal myasthenia. Neurol Genet 2016;2:e105.
7. O'Connor E, Topf A, Muller JS, et al. Identification of mutations in the MYO9A gene in patients with congenital myasthenic syndrome. Brain 2016;139:2143–2153.
8. Bauche S, O'Regan S, Azuma Y, et al. Impaired presynaptic high-affinity choline transporter causes a congenital myasthenic syndrome with episodic apnea. Am J Hum Genet 2016;99:753–761.
9. O'Grady GL, Verschuuren C, Yuen M, et al. Variants in SLC18A3, vesicular acetylcholine transporter, cause congenital myasthenic syndrome. Neurology 2016;87:1442–1448.
10. Sudhof TC. Neurotransmitter release: the last millisecond in the life of the synaptic vesicle. Neuron 2013;80:675–690.
11. Liu Y, Sugiura Y, Lin W. The role of synaptobrevin1/VAMP1 in Ca2+-triggered neurotransmitter release at the mouse neuromuscular junction. J Physiol 2011;589:1603–1618.
12. Zimmermann J, Trimbuch T, Rosenmund C. Synaptobrevin 1 mediates vesicle priming and evoked release in a subpopulation of hippocampal neurons. J Neurophysiol 2014;112:1559–1565.
13. Isenmann S, Khew-Goodall Y, Gamble J, et al. A splice-isoform of vesicle-associated membrane protein-1 (VAMP-1) contains a mitochondrial targeting signal. Mol Biol Cell 1998;9:1649–1660.
14. O'Connor DT, Mahata SK, Mahata M, et al. Primary culture of bovine chromaffin cells. NatProtoc 2007;2:1248–1253.
15. Shen XM, Deymeer F, Sine SM, Engel AG. Slow-channel mutation in AChR αM4 domain and its efficient knockdown. Ann Neurol 2006;60:128–136.
16. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016;536:285–291.
17. Archer BT 3rd, Ozcelik T, Jahn R, et al. Structures and chromosomal localizations of two human genes encoding synaptobrevins 1 and 2. J Biol Chem 1990;265:17267–17273.
18. Berglund L, Hoffmann HJ, Dahl R, Petersen TE. VAMP-1 has a highly variable C-terminus generated by alternative splicing. Biochem Biophys Res Commun 1999;264:777–780.
19. Khmelinskii A, Meurer M, Ho CT, et al. Incomplete proteasomal degradation of green fluorescent proteins in the context of tandem fluorescent protein timers. Mol Biol Cell 2016;27:360–370.
20. Borisovska M, Zhao Y, Tsytsyura Y, et al. v-SNAREs control exocytosis of vesicles from priming to fusion. EMBO J 2005;24:2114–2126.
21. Grant NJ, Hepp R, Krasuse W, et al. Differential expression of SNAP-25 isoforms and SNAP-23 in the adrenal gland. Neuro Chem 1999;72:363–372.
22. Gonon F, Cespuglio R, Ponchon JL, et al. In vivo continuous electrochemical determination of dopamine release in rat neostriatum. C R Acad Sci Hebd Seances Acad Sci D 1978;286:1203–1206.
23. Leszczyszyn DJ, Jankkowski JA, Viveros OH, et al. Nicotinic receptor-mediated catecholamine release from individual chromaffin cell. J Biol Chem 1990;265:14736–14737.
24. Wightman RM, Jankowski JA, Kennedy RT, et al. Temporarily resolved catecholamine spikes correspond to single vesicle release from individual chromaffin cells. Proc Natl Acad Sci USA 1991;88:10754–10758.
25. Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann NY Acad Sci 1971;183:183–199.
26. Koo SJ, Kochlamazashvili G, Rost B, et al. Vesicular synaptobrevin/VAMP2 levels guarded by AP180 control efficient neurotransmission. Neuron 2015;88:330–344.
27. Adams DJ, Arthur CP, Stowell MH. Architecture of the synaptophysin/synaptobrevin complex: structural evidence for an entropic clustering function at the synapse. Sci Rep 2015;5:13659.
28. Rajappa R, Gauthier-Kemper A, Boning D, et al. Synaptophysin 1 clears synaptobrevin 2 from the presynaptic active zone to prevent short-term depression. Cell Rep 2016;14:1369–1381.
29. Dhara M, Yarzagaray A, Makke M, et al. v-SNARE transmembrane domains function as catalysts for vesicle fusion. eLife 2016; 5:e17571.
30. Ngatchou AN, Kisler K, Fang Q, et al. Role of the synaptobrevin C terminus in fusion pore formation. Proc Natl Acad Sci USA 2010;107:18463–18468.
31. Lindau M, Hall BA, Chetwynd A, et al. Coarse-grain simulations reveal movement of the synaptobrevin C-terminus in response to piconewton forces. Biophys J 2012;103:9959–9969.
32. Fang Q, Lindau M. How could SNARE proteins open a fusion pore? Physiology (Bethesda) 2014;29:278–285.
33. Nystuen AM, Schwendinger JK, Sachs AJ, et al. A null mutation in VAMP1/synaptobrevin is associated with neurological defects and prewean mortality in the lethal-wasting mouse mutant. Neurogenetics 2007;8:1–10.
34. Bourassa CV, Meijer IA, Merner ND, et al. VAMP1 mutation causes dominant hereditary spastic ataxia in Newfoundland families. Am J Hum Genet 2012;91:548–552.